Skip to main content
OpenTrials
Completed

NCT Number: NCT03553173

So-Lo-Mo Intervention Applied to the Smoking Cessation Process

This is a randomized open-label parallel-group trial. 240 subjects will be recruited during 8 months and a 12 months follow-up will be carried out for each one of them. The sample will split in two groups: control group (n=120) who will receive usual psycho-pharmacological therapy and the intervention group (n=120) who will receive usual therapy plus So-Lo-Mo app.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Smoking Cessation Alzheimer Disease Behavior Brain Diseases Central Nervous System Diseases Dementia Health Behavior Lifestyle-related Condition Mental Disorders Nervous System Diseases Neurocognitive Disorders Neurodegenerative Diseases Tauopathies

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

About this study

The main objective of this study is to analyze the efficacy and efficiency of the So-Lo-Mo intervention applied to the smoking cessation process compared to usual care.

Secondary objectives are:

  • To monitor usual psycho-pharmacological therapies (bupropion, varenicline and behavioural therapy).
  • To monitor healthy lifestyle and physical exercise habits.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Smoking population attending to the Smoking Cessation Unit of "Virgen del Rocío" University Hospital.
  • Subjects >18 years old who want to give up smoking.
  • Android-based smart phone availability.
  • Ability to interact with the smart phone.
  • To sign an Informed Consent Form.

Exclusion criteria

  • Subjects had some previous adverse effects related to the pharmacological treatment included in the study

Treatment and study plan

So-Lo-Mo

Other

So-Lo-Mo is an innovative intervention based on mobile technologies and its capacity to trigger behavioral changes. In this sense, the App is a complement to pharmacological therapies to quit smoking providing personalised motivational messages, physical activity monitoring, lifestyle advices and distractions (mini-games) to help pass the cravings. The main objective of this App is to improve patient's adherence to the smoking cessation process making use of behavioral techniques in the form of motivational messages and/or Short Message Service (SMS).

Other names: SoLoMo

Psychological advice

Behavioral

Provision of information about smoking and smoking cessation process, as well as supporting behavioral changes through the provision of new skills and strategies. The most used methods are the motivational interview and the cognitive-behavioral therapy

Other names: Behavioral

Bupropion Pill

Drug

Formulated as a 150 mg long discharge pill, usually being prescribed a daily dose of 300 mg, except for week one which would be prescribed 150 mg per day. The usual length of the treatment ranges from 7 to 9 weeks. However, 12 weeks treatments could be prescribed for severe cases of smokers.

Other names: Bupropion

Varenicline Pill

Drug

Formulated as 0,5 mg and 1 mg pills, and the dose should be progressively incremented during the first days in order to facilitate tolerance. The recommended length of the treatment is 12 weeks, although longer treatments could be necessary for severe smokers.

Other names: Varenicline

Primary outcomes

  1. Efficacy: Smoking abstinence rate

    Time frame: 1 year

    Smoking abstinence rate at 1 year measured by means of exhaled Carbon Monoxide (CO) and urinary cotinine tests. Subjects with cotinine concentrations >200 ng/ml or CO >6 ppm will be considered as smokers.

  2. Efficiency: Incremental Cost-Effectiveness Ratio

    Time frame: 1 year

    Expressed in terms of Incremental Cost-Effectiveness Ratio (ICER), calculated by dividing the difference in total costs between the intervention group and the control group by the difference in Quality-Adjusted Life Year (QALY) between both groups. Costs associated to control and intervention groups will include healthcare resources utilization measured in terms of specialist consultations related to the smoking cessation process. Costs of pharmacological treatment and time employed by healthcare professionals during the design phase will also be taken into account. Benefit for patients will be expressed in terms of QALY. EuroQol-5D-5L questionnaire will be used to estimate QALY.

Secondary outcomes

  1. Incidence of Treatment-Related Adverse Events [Safety]

    Time frame: 1 year

    To monitor usual pharmacological therapies (bupropion and varenicline) in order to gather the incidence of related adverse events reported. Safety will be measured as the number of adverse events related to pharmacological therapies. The following adverse events have been identified related to each pharmacological therapy:

    Varenicline: Nausea, vomit, headache, insomnia, abnormal dreams, constipation and flatulence.

    Bupropion: insomnia, headache, dryness in the mouth, alteration of taste, skin reactions, convulsions, cardiovascular side effects and severe skin reactions.

  2. International Physical Activity Questionnaire (IPAQ27) score [Physical activity]

    Time frame: From baseline (first evaluation in the study) to 1 year after

    Physical activity will be measured in terms of the International Physical Activity Questionnaire (IPAQ27) score calculation at baseline (first evaluation in the study) and at the end of the intervention (after 1 year of follow-up). The result is expressed as metabolic equivalent (MET)-minutes per week. Interpretation:

    • Low: Individuals who not meet criteria for categories 2 or 3 are considered 'low'
    • Moderate: 3 or more days of vigorous-intensity activity of at least 20 minutes per day OR 5 or more days of moderate-intensity activity and/or walking of at least 30 minutes per day OR 5 or more days of any combination of walking, moderate-intensity or vigorous intensity activities achieving a minimum Total physical activity of at least 600 MET-minutes/week
    • High: vigorous-intensity activity on at least 3 days achieving a minimum Total physical activity of at least 1500 MET-minutes/week

  3. Body Mass Index (BMI) in kg/m^2 [Healthy lifestyle]

    Time frame: From baseline (first evaluation in the study) to 1 year after

    Healthy lifestyle will be measured in terms of the subject's BMI (weight in kg / height in m^2) at baseline (first evaluation in the study) and at the end of the intervention (after 1 year of follow-up).

Sponsors and collaborators

Lead sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

Other

Collaborators

  • Andaluz Health Service
  • European Commission

Registry information

Official study title

A Randomized Open-label Parallel-group Trial is to Analyze the Efficacy and the Efficiency of the Social-Local-Mobile (So-Lo-Mo) Intervention Applied to the Smoking Cessation Process.

Acronym: So-Lo-Mo

Important dates

Study start
2016
Primary completion
2018
Study completion
2018
First posted
Jun 12, 2018
Registry last updated
Dec 4, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.